Co-Enzyme Q10 to treat neurological disorders: Basic mechanisms, clinical outcomes, and future research direction
- Mohamed Salama,
- Ti Fei Yuan,
- Sergio Machado,
- ,
- José A. Vega,
- Manuel Menéndez-González
- Mansoura University,
- NCI,
- Universidade Salgado de Oliveira,
- Universidade Federal de Uberlândia,
- Universidade Federal do Rio de Janeiro,
- Universidad Central de Chile
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 641-644 (4 pages)Journal (Volume, Issue Number)
CNS and Neurological Disorders - Drug Targets (Volume 12, Issue 5)Publication milestones
- Published - 28/08/2013
Publication status
ISSN
1871-5273Publication IDs
- Scopus: 84882763118
Abstract
Coenzyme Q10 (CoQ10) is critical for the cell power supply in mitochondria. CoQ10 shuttles electrons from complexes I and II to complex III, and can be anti-oxdiative. Neurons require high energy for synaptic transmission and therefore the mitochondria dysfunction often leads to severe neuronal degeneration, as observed in many neurological disorders. CoQ10 supplementation has been widely used to treat aging, stroke, neuromuscular diseases, Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, autosomal recessive cerebellar ataxias, Huntington's disease and amyotrophic lateral sclerosis. Here we discuss a large number of preclinical and clinical trials for CoQ10 to elucidate the mechanisms underlying CoQ10 therapy. The rational applications as a therapeutic agent in neurological disorders are discussed.
